Institute for Biomedical Research, University of Birmingham, Birmingham, UK.
Rev Med Virol. 2012 May;22(3):182-93. doi: 10.1002/rmv.723. Epub 2012 Mar 6.
HCV is a blood-borne pathogen that affects approximately 3% of the global population and leads to progressive liver disease. Recent advances have identified an essential role for host cell molecules: tetraspanin CD81, scavenger receptor B1 and the tight junction proteins claudin-1 and occludin in HCV entry, suggesting a complex multi-step process. The conserved nature of this receptor-dependent step in the viral life cycle offers an attractive target for therapeutic intervention. Evidence is emerging that additional factors other than classical receptors, such as inflammatory mediators regulate the ability of hepatocytes to support HCV entry, and as such may provide potential avenues for drug design and development. In this review, we summarise the recent literature on HCV entry mechanisms with a view to realising the future potential of therapeutically targeting this process.
HCV 是一种血源性病原体，影响全球约 3%的人口，并导致进行性肝病。最近的研究进展确定了宿主细胞分子在 HCV 进入中的重要作用：四跨膜蛋白 CD81、清道夫受体 B1 以及紧密连接蛋白 claudin-1 和 occludin，表明这是一个复杂的多步骤过程。在病毒生命周期中，这种受体依赖性步骤的保守性质为治疗干预提供了一个有吸引力的靶点。有证据表明，除了经典受体之外，其他因素（如炎症介质）调节肝细胞支持 HCV 进入的能力，因此可能为药物设计和开发提供潜在途径。在这篇综述中，我们总结了 HCV 进入机制的最新文献，以期实现靶向该过程的治疗潜力。
